source
- Takeda’s long-term R&D head announces exit after major pipeline reorganizationA few months after a new CEO stepped up to helm Takeda, the drugmaker will now have to prepare for another leadership change as its long-time R&D head plans his exit.BioSpace · 48m ago↗ source
- Why two promising heart drugs flopped and what’s nextThis week on "The Readout LOUD" podcast: Two experimental drugs were heralded as the next era in heart disease treatment — why did they fail?STAT · 58m ago↗ source
- Novo Nordisk halts two IL-6 heart trials as Novartis suffers Phase 3 setbacks; Ionis wins first Alexander disease approvalNovo Nordisk announced it has ended two late‑stage studies of its investigational IL‑6 inhibitor ziltivekimab, which was being evaluated for cardiovascular disease. The decision follows an earlier…